Screening for Incidental Adrenal Abnormalities on Imaging

Abstract

Incidental adrenal abnormalities detected through imaging studies have become increasingly prevalent with the widespread use of advanced radiological modalities. This review synthesizes the current understanding of the epidemiology, pathophysiology, risk factors, clinical features, diagnostic strategies, management protocols, recent advances, and guideline recommendations for the screening and evaluation of incidentally discovered adrenal lesions. Emphasis is placed on evidence-based algorithms, the clinical relevance of distinguishing benign from malignant etiologies, and the practical implications for endocrinologists, radiologists, and primary care providers. The article elucidates the complexities inherent in decision-making for incidental adrenal masses, aiming to optimize patient outcomes while minimizing unnecessary interventions.

Introduction

The detection of adrenal incidentalomas—unexpected adrenal masses identified during imaging performed for unrelated indications—has risen sharply in recent decades. The phenomenon is largely attributable to the proliferation of high-resolution computed tomography (CT), magnetic resonance imaging (MRI), and ultrasonography, which are routinely used in the evaluation of abdominal and thoracic complaints. While most adrenal incidentalomas are benign and non-functioning, a minority may represent hormonally active or malignant lesions, necessitating a nuanced approach to risk stratification and management. This review addresses the epidemiological trends, underlying mechanisms, and evolving clinical strategies for the screening of incidental adrenal abnormalities, providing a comprehensive synthesis for healthcare professionals navigating this increasingly common clinical scenario.

Epidemiology / Disease Burden

Adrenal incidentalomas are encountered in approximately 2-7% of abdominal imaging studies, with prevalence increasing with age. Autopsy series corroborate these findings, revealing a detection rate as high as 8% in elderly populations. The majority (over 80%) of incidentally discovered adrenal masses are benign adrenocortical adenomas, while the remainder may include myelolipomas, cysts, pheochromocytomas, metastases, and primary adrenocortical carcinomas. The overall burden on healthcare systems is substantial, given the frequency of cross-sectional imaging and the ensuing cascade of diagnostic and therapeutic interventions. Population-based studies highlight the need for judicious screening protocols to avoid overtreatment while ensuring timely identification of clinically significant lesions.

Pathophysiology

The adrenal glands are susceptible to a wide spectrum of pathological processes, ranging from benign hyperplasia and adenoma formation to malignant transformation. Most incidental lesions arise from cortical cells and are non-functioning; however, aberrant steroidogenesis can lead to subclinical or overt hormonal excess, including cortisol (Cushing syndrome), aldosterone (Conn syndrome), or catecholamine (pheochromocytoma) overproduction. The molecular underpinnings of adrenocortical tumorigenesis involve dysregulation of the Wnt/β-catenin pathway, mutations in PRKAR1A, and alterations in cell cycle regulators. Malignant transformation may be associated with TP53 mutations and chromosomal instability. Understanding these mechanisms is essential for interpreting imaging characteristics and guiding subsequent management.

Risk Factors

Risk factors for incidental adrenal abnormalities include advanced age, hypertension, obesity, diabetes, and a history of malignancy. Patients with hereditary syndromes such as Multiple Endocrine Neoplasia type 1 (MEN1), Li-Fraumeni, or familial pheochromocytoma-paraganglioma syndromes are at elevated risk for adrenal tumors. Additionally, individuals with a prior history of extra-adrenal malignancy warrant thorough assessment for metastatic disease when adrenal lesions are discovered. The risk of functional lesions is modest but clinically significant, necessitating a high index of suspicion in patients with suggestive symptomatology or biochemical derangements.

Clinical Features

Most patients with adrenal incidentalomas are asymptomatic at the time of discovery. Clinical features, when present, are typically related to hormonal hypersecretion. Signs of cortisol excess may include central obesity, skin changes, hypertension, and glucose intolerance. Aldosterone-producing adenomas often manifest as resistant hypertension and hypokalemia. Pheochromocytomas can cause episodic hypertension, palpitations, headaches, and diaphoresis. Non-functioning adenomas and benign cysts are generally silent, whereas malignant lesions may present with constitutional symptoms or evidence of metastatic disease.

Diagnosis

The diagnostic workup of incidental adrenal lesions is guided by a combination of radiological assessment and biochemical testing. Imaging modalities such as unenhanced and contrast-enhanced CT, MRI with chemical shift imaging, and, in selected cases, positron emission tomography (PET) are pivotal in characterizing adenomas based on size, morphology, and attenuation values. Lesions with low Hounsfield units (<10 HU on unenhanced CT) and rapid contrast washout are typically benign. Biochemical evaluation involves screening for autonomous cortisol secretion (overnight dexamethasone suppression test), aldosteronism (plasma aldosterone-renin ratio), and catecholamine excess (plasma free metanephrines or 24-hour urinary catecholamines). The integration of imaging and hormonal data enables risk stratification and informs management decisions.

Treatment & Management

Management of incidental adrenal abnormalities is individualized based on lesion size, imaging characteristics, functional status, and patient comorbidities. Non-functioning lesions less than 4 cm with benign imaging features are typically monitored with interval imaging, whereas masses exceeding 4-6 cm, showing interval growth, or possessing indeterminate features may warrant surgical excision. Functioning tumors are generally treated with adrenalectomy. Multidisciplinary collaboration among endocrinologists, radiologists, and surgeons is essential for optimal care. Careful patient counseling regarding the risks of surgery, adrenal insufficiency, and the natural history of benign tumors is mandatory.

Recent Advances / Emerging Therapies

Recent years have seen advancements in imaging technology, including dual-energy CT and functional MRI, enhancing the ability to differentiate benign from malignant lesions non-invasively. Molecular biomarkers and next-generation sequencing are under investigation for refining risk assessment and targeting therapy in adrenocortical carcinoma. Minimally invasive surgical techniques, such as laparoscopic and robotic adrenalectomy, have reduced morbidity and improved recovery times. Artificial intelligence (AI)-driven algorithms are being developed to automate lesion characterization and risk prediction, potentially streamlining the diagnostic workflow and reducing interobserver variability.

Guideline Recommendations

Current guidelines from the European Society of Endocrinology, American Association of Clinical Endocrinologists, and Endocrine Society advocate a structured approach to the evaluation of adrenal incidentalomas. Key recommendations include comprehensive hormonal assessment for all patients, imaging-based risk stratification, and consideration of surgical intervention for lesions with high-risk features or confirmed hormonal activity. Repeat imaging at 6-12 months is advised for indeterminate lesions, with cessation of follow-up in stable, benign-appearing masses after 1-2 years. Multidisciplinary case discussions and patient-centered decision-making are emphasized to balance the risks of intervention against the potential for malignancy or hormonal complications.

Conclusion

Incidental adrenal abnormalities on imaging represent a complex clinical challenge, necessitating a systematic, evidence-based approach to screening, diagnosis, and management. Advances in imaging, molecular diagnostics, and minimally invasive therapies are reshaping the clinical landscape, facilitating more precise risk stratification and individualized care. Ongoing research to refine diagnostic algorithms and elucidate molecular mechanisms will further enhance the ability of clinicians to optimize outcomes and minimize unnecessary interventions in patients with adrenal incidentalomas.